Cytheris Reports Promising Results From Phase I/II HIV Trial
Posted on: Wednesday, 13 February 2008, 12:00 CST
Cytheris has reported positive results of the long-term follow-up of patients in a multi-center Phase I/II study of Interleukin-7/IL-7 therapy in chronically HIV-1 infected patients, whose CD4+ T-cell counts remained low despite treatment with anti-retroviral-therapies or HAART.
The Phase I/II trial was designed to investigate the safety of IL-7 therapy in chronically HIV-1 infected patients with low CD4 counts (100-400 CD4+/µl) and plasma HIV RNA <50 cp/ml for at least six months while on HAART.
The long-term results for this group of patients, defined as immune non-responders, indicate that the IL-7 induced rapid expansion of CD4+ and CD8+ T-cell counts was sustained up to 48 weeks from study entry. Importantly, 48 weeks after initiation of this IL-7 short course of treatment, patients treated at the 10µg/kg dose level showed a median increase in CD4+ and CD8+ T-cell counts (cells/µL) of 75% and 57%, respectively, from baseline levels.
Source: Datamonitor
Related Articles
- Largest Study to Date Compares Cholesterol Treatment in HIV Patients & Patients Without HIV Infection
- Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients
- Cytheris Announces 48-Week Results of Phase I/II Study Showing Administration of Interleukin-7 (IL-7) Significantly Improves CD4 T-Cell Counts in Chronically Infected HIV-1 Patients
- Transplants May Be Easier for HIV Patients
- What is Your Patient Taking? Dietary Supplements in an HIV-Positive Patient
- Serum Neopterin Levels in HIV Infected Patients With & Without Tuberculosis
- Oral Candidiasis in Pediatric HIV Patients
- Pa. Hospital Urges Colon Patient HIV Tests
- Nurse Seeks Order for Patient's HIV Test
 |
 |
User Comments (0)
RSS Feeds